Bell Potter Downgrades Sigma Healthcare Shares
The brokerage firm maintains a price target of $3.00 following a recent stock rally.
Updated on Oct. 19, 2026 in Healthcare
Live Poll
Is now a good time to hold stocks that have experienced recent rapid growth?
Bell Potter has downgraded Sigma Healthcare shares from buy to hold as the stock price reached fair value. The company recently recorded 14.7% like-for-like network sales growth in 1Q FY26.
Why it matters
The downgrade reflects a cooling sentiment after Sigma Healthcare shares gained approximately 13% since mid-September. The shift is attributed to investors seeking safety away from tech stocks, bringing the valuation in line with growth expectations.
Sigma Healthcare shares have gained 13% since mid-September, with the stock currently priced at $2.83 against a $3.00 target. The company reported 14.7% like-for-like network sales growth in 1Q FY26.
The players
Bell Potter
Bell Potter is an Australian-based full-service stockbroking and financial advisory firm.
Sigma Healthcare
Sigma Healthcare is a leading Australian pharmacy chain and pharmaceutical wholesaler.
The details
Private prescriptions for GLP-1 medications currently represent 44% of all total prescriptions sold in Australia. The broker projections suggest 1Q27 network like-for-like sales growth will range between 12% and 13%.
Timeline
September 2026 marked the start of the Sigma Healthcare share rally.
21 October 2026 is the date of the Sigma Healthcare annual general meeting.
Late 2026 is the expected timeframe for TGA approval of the oral formulation of Mounjaro.
Market Landscape
This downgrade follows a broader market valuation trend driven by intense demand for GLP-1 medications in Australia. The shift positions the company at fair value after a rally fueled by a flight to safety among local investors.
Retail investors may note the brokerage recommendation indicates the share price has reached fair value, limiting short-term upside potential. The company's performance remains heavily tied to the popularity of GLP-1 medications in the Australian market.
The takeaway
Investors should monitor the upcoming 3-month trading update for insights into sustained growth beyond the current rally. The long-term outlook remains tethered to TGA approvals and the continued market penetration of specific weight-loss medications.
What happens next
Sigma Healthcare is expected to provide a 3-month trading update at the annual general meeting on 21 October 2026.
Further reading
For more analysis on the local sector, visit Australia Healthcare.
Live Poll
Is now a good time to hold stocks that have experienced recent rapid growth?
